Skip to content

Text messages in psoriasis

Text messages as a reminder and educational tool in patients with psoriasis: A pilot study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12622001042730
Enrollment
33
Registered
2022-07-26
Start date
2020-09-30
Completion date
2020-11-25
Last updated
2022-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Background: Psoriasis is a chronic inflammatory disease of the skin with subsequent systemic comorbidities significantly affecting quality of life. Successful management requires consistent treatment adherence, yet treatment dissatisfaction and suboptimal adherence to medication is a common and complex problem among people living with this chronic illness. Objectives: To evaluate the use of text messages (TM) in improving treatment adherence and several patient outcomes such as disease severity, quality of life, and the patient–physician relationship Relevance: The study aims to minimize health care costs by using TM as an innovative, low-cost, and promising way of improving adherence to medication among patients with psoriasis thru an evidence-based study6, thereby improving patient satisfaction and quality of life.

Interventions

Patients actively seen via telemedicine at least every 2 weeks (convenience sampling) were invited to join the study. Randomization was done by a computer-generated random number list to group assignment, which was stored electronically. Patients assigned to the text message (TM) group received 7 TM per week (1 TM per day) whereas patients assigned to the control group received none all throughout the study. The patients in the TM group will be receiving 7 TM per week (1 TM per day) for a period

Patients actively seen via telemedicine at least every 2 weeks (convenience sampling) were invited to join the study. Randomization was done by a computer-generated random number list to group assignment, which was stored electronically. Patients assigned to the text message (TM) group received 7 TM per week (1 TM per day) whereas patients assigned to the control group received none all throughout the study. The patients in the TM group will be receiving 7 TM per week (1 TM per day) for a period of 12 weeks in the same randomly selected order (reminders three times weekly and educational tools four times weekly), as outlined by Balato et al in "Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis" published in the British Journal of Dermatology last 2013. Each TM was 1-2 sentences in length, and was created using simple language, considering frequently asked questions about psoriatic drugs (e.g. administration, adverse effects) and general recommendations to take care of overall health. Research participants were assessed in four study visits, one at the beginning and every 2 weeks thereafter until the eighth week. The following assessments were performed in all patients by the physicians: skin severity using Psoriasis Area and Severity Index (PASI), body surface area (BSA) and Physicians Global Assessment (PGA). After the skin evaluations, participants were asked to answer self-administered questionnaires that measured the following: quality of life using the Dermatology Life Quality Index (DLQI) and treatment adherence using the Medication Adherence Questionnaire (MAQ). An evaluation of the patient–physician relationship (through a 0–10 scale questionnaire) was also assessed during the first visit as baseline. After 8 weeks of receiving daily TM, participants returned for a final evaluation and were asked to answer the same surveys, with added survey forms on evaluation of the patient–physician relationship and usability and satisfaction with TM interventions. The physicians who observed and examined the patients were blinded to the TM or control group assignment. The primary investigator, on the other hand, was the one who enrolled, randomized, and sent daily TM to the patients. Furthermore, it was also the primary investigator who made the patients answer the patient-physician relationship satisfaction questionnaire at the end of the study.

Sponsors

Jennifer Lavina T. Ngo
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Primary purpose
Educational / counselling / training

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Patients whose PASI score were between 5 and 25 while receiving topical and physical or systemic treatment were included in this study. Other eligibility factors included the ability to acquire medications, ownership of a cellular phone, and the capacity to acknowledge the receipt of daily text messages.

Exclusion criteria

Patients with psoriasis who refuse to give and sign the consent form were excluded.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026